Bausch & Lomb (BLCO) Net Income towards Common Stockholders (2021 - 2026)
Bausch & Lomb (BLCO) reported Net Income towards Common Stockholders of -$70.0 million for Q1 2026, up 66.82% on a YoY basis from -$42.0 million in Q1 2025, and down 20.69% quarter-over-quarter from -$58.0 million in Q4 2025.
Bausch & Lomb (BLCO) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Bausch & Lomb has reported Net Income towards Common Stockholders for 6 years, with the latest figure at -$70.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 66.82% year-over-year to -$70.0 million; the trailing twelve-month figure through Mar 2026 stood at -$211.0 million (up 40.23% YoY), and the FY2025 full-year result was -$352.0 million, down 15.41% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$70.0 million, down from -$58.0 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $23.0 million in Q1 2022, with the low at -$211.0 million in Q1 2025.
- Historically, Net Income towards Common Stockholders has averaged -$60.0 million across 5 years, with a median of -$54.5 million in 2023.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 110.0% — and 2025, when it plunged 2800.0%.
- Bausch & Lomb's Net Income towards Common Stockholders stood at -$15.0 million in 2022, then slumped by 240.0% to -$51.0 million in 2023, then surged by 96.08% to -$2.0 million in 2024, then sank by 2800.0% to -$58.0 million in 2025, then declined by 20.69% to -$70.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$70.0 million (Q1 2026), -$58.0 million (Q4 2025), and -$25.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 826.00 Mn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -274.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 239.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 398.73 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 135.40 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 13.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -77.90 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 112.77 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 2.00 Mn |
| 10 | Bausch & Lomb | 5.32 Bn | 5.12 Bn | 973.00 Mn | -70.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -70.00 Mn |
| Dec 31, 2025 | -58.00 Mn |
| Sep 30, 2025 | -25.00 Mn |
| Jun 30, 2025 | -58.00 Mn |
| Mar 31, 2025 | -211.00 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Sep 30, 2024 | 8.00 Mn |
| Jun 30, 2024 | -148.00 Mn |
| Mar 31, 2024 | -163.00 Mn |
| Dec 31, 2023 | -51.00 Mn |
| Sep 30, 2023 | -80.00 Mn |
| Jun 30, 2023 | -29.00 Mn |
| Mar 31, 2023 | -88.00 Mn |
| Sep 30, 2022 | -15.00 Mn |
| Jun 30, 2022 | 7.00 Mn |
| Mar 31, 2022 | 23.00 Mn |
| Dec 31, 2021 | 54.00 Mn |
| Sep 30, 2021 | 63.00 Mn |
| Jun 30, 2021 | 46.00 Mn |
| Mar 31, 2021 | 30.00 Mn |